Inhibitory effect of concomitantly administered rabies immunoglobulins on the immunogenicity of commercial and candidate human rabies vaccines in hamsters

Marie-Clotilde Bernard*†, Florence Boudet, Andrea-Clemencia Pineda-Peña & Françoise Guinet-Morlot

The World Health Organization protocol for rabies post-exposure prophylaxis (PEP) recommends extensive wound washing, immediate vaccination, and administration of rabies immunoglobulin (RIG) in severe category III exposures. Some studies have shown that RIG can interfere with rabies vaccine immunogenicity to some extent. We investigated the interference of RIG on a next generation highly purified Vero cell rabies vaccine candidate (PVRV-NG) versus standard-of-care vaccines in a previously described hamster model. The interference of either human (h) or equine (e) RIG on the immune response elicited by PVRV-NG, Verorab® (purified Vero cell rabies vaccine, PVRV), and Imovax® Rabies (human diploid cell rabies vaccine; HDCV) was evaluated using the 4-dose Essen PEP regimen. The anti-rabies seroneutralizing titers and specific serum IgM titers were measured by fluorescent antibody virus neutralization test and enzyme-linked immunosorbent assay, respectively, for the vaccines administered with or without RIG. The RIG interference on PVRV-NG, observed transiently at Day 7, was similar to that on PVRV and tended to be lower than that on HDCV using both read-outs. In summary, the results generated in the hamster model showed that RIG induced similar or less interference on PVRV-NG than the standard-of-care vaccines.

Rabies is a major neglected tropical disease present across continents and predominantly affects vulnerable rural populations in Asia and Africa. Rabies is an acute progressive viral encephalomyelitis, estimated to cause 59,000 human deaths and over 3.7 million disability-adjusted life years (DALYs) loss every year. Dogs are the main source of human rabies, contributing to 99% of all rabies transmissions to humans. There is no cure for rabies; hence, timely and proper post-exposure prophylaxis (PEP) is needed to effectively prevent clinical manifestations of rabies. Standard PEP consists of chemical or biological inactivation of the virus at the site of exposure, followed by a series of vaccine injections. Every year, more than 29 million people worldwide receive PEP for management of rabies exposure, resulting in a notable reduction in mortality rate. Passive immunization with human (h) or equine (e) rabies immunoglobulin (RIG) at the site of the wound in the PEP regimen is considered mandatory for “Category III” exposures corresponding to severe wounds. RIG is injected directly to neutralize the virus before an active response of the vaccine is augmented in individuals who have not previously been vaccinated against rabies. eRIG is preferentially used in endemic countries compared with hRIG due to its low cost; both have shown similar clinical outcomes in preventing rabies. The maximum RIG dose is 20 international units (IU)/kg and 40 IU/kg of body weight for hRIG and eRIG, respectively. The dose should not exceed the recommended limit as it may interfere with the active antibody responses. The RIG should be administered as soon as possible after the rabies exposure in the wound up to the seventh day post-exposure when active antibody response to rabies vaccine has started to develop.
Vaccination is the only effective preventive measure against rabies and rabies vaccines can be administered either as pre-exposure prophylaxis or PEP using different regimens or schedules. The World Health Organization (WHO) recommendations for intra-muscular (IM) PEP include mainly the 4-dose Essen regimen in individuals not previously immunized (1 IM injection at Days 0, 3, 7, and between Days 14 and 28), although the 5-dose Essen regimen with a fifth dose at Day 28 may still be recommended in some national guidelines. Other IM and intradermal (ID) schedules are also recommended. Several rabies vaccines have been developed, including but not limited to human diploid cell rabies vaccine (HDCV, Imovax® Rabies, Sanofi) in the 1970's and purified Vero cell rabies vaccine (PVRV, Verorab®, Sanofi) in the early 1980's. Increased disease awareness and development of next generation vaccines are warranted to effectively prevent the infection. With the aim to continue the legacy of innovation, Sanofi is developing a serum-free, highly purified Vero cell rabies vaccine (PVRV-NG) to provide a next generation (NG) of rabies vaccine using the state-of-the-art technology. The PVRV-NG vaccine has been developed using the same Pitman-Moore viral strain as PVRV and HDCV. It is a highly purified form of PVRV, without human or animal-derived components (in particular, no human or animal-derived serum or human serum albumin) and antibiotic-free. In addition, the process involves the reduction of residual cell substrate deoxyribonucleic acid (DNA) to ≤ 100 pg/dose. PVRV-NG is currently under Phase III clinical development.

Commercial rabies vaccines are among the most immunogenic vaccines, rapidly inducing high rabies virus neutralizing antibody (RVNA) levels in response to the rabies virus G protein. As an adequate response to vaccination has been accepted by the WHO and regulatory agencies as study endpoints in clinical trials of novel rabies vaccines. In most individuals, this level is reached within a few weeks of the first vaccine dose. In PEP regimen with co-administration of RIG, the delay in immune response development to rabies vaccine may be increased due to transient immuno-suppressive effect of the RIG regardless of the vaccination regimen used. Results from clinical trials have shown seroconversion ranging between 80 and 100% at Day 14, whereas in real-world observational cohort studies, seroconversion ranged between 93 and 100% even at Day 28 using IM PEP regimens with different licensed vaccines co-administered with RIG. These data indicate that, in clinical trials and observational studies, seroconversion of 100% was not always achieved at Day 14 when RIG was co-administered with the vaccine.

Therefore, in the context of developing a new rabies vaccine, the objective of the study was to evaluate the immunogenic interference induced by RIG on the PVRV-NG vaccine candidate versus that seen with PVRV and HDCV, the two commercially available rabies vaccines considered as standard-of-care, in a previously described hamster model using PEP 4-dose Essen regimen.

Materials and methods

Animals. All experiments were performed on female Syrian golden hamsters in animal facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. The preliminary experiment and experiment 1 were performed at Voxcan, France and experiment 2 was conducted at Sanofi, Marcy l’Etoile, France. For preliminary experiment and experiment 1, the project and the study protocols were approved by the Ethics Committee of Voxcan France. For experiment 2, the experimental setup was reviewed and preapproved by the Ethics Committee #11 of Sanofi. All experiments were conducted in accordance with the European Directive 2010/63/EU. This study is reported in accordance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.

Female Syrian golden hamsters were purchased from Janvier Labs (France). They were housed in clean polypolypropylene cages (3 hamsters per cage) and fed standard irradiated laboratory food and water ad libitum. Hamsters were acclimated to their designated housing for 1 week before vaccination. Environmental enrichment was provided by addition of wood brick, paper strip, and cardboard tube for the preliminary experiment and experiment 1, and one tube cardboard, a wheel of exercise, and a square of nestlet type in each cage for experiment 2. At the time of experiments, hamsters weighed 100 g average at Day 0 of the experiment and were around 8 weeks of age. Animals were randomly assigned to treatment or control groups by cage. Additionally, randomization of the allocation of cages was performed according to an internal statistical software. Allocation of 12 animals per treatment group was defined according to a study by De Benedictis et al.17. The decision to allocate 6 (experiment 1) or 3 (experiment 2) animals to each of the RIG control groups were based on the findings of the preliminary experiment and corresponding ethical reasons. No blinding of investigator was implemented. No samples nor animals were excluded from the analyses.

The animals were administered with vaccines and immunoglobulins and adverse events were not expected. Animals were observed daily for clinical symptoms with attention to the injected hind legs. Even though serious clinical symptoms were not expected, several ethical endpoints were defined prior starting the study in compliance with the ethical committee recommendations to avoid animal suffering. Body weight loss > 20% of the initial body weight at Day 5 was provided by addition of wood brick, paper strip, and cardboard tube for the preliminary experiment and experiment 1, and one tube cardboard, a wheel of exercise, and a square of nestlet type in each cage for experiment 2. At the time of experiments, hamsters weighed 100 g average at Day 0 of the experiment and were around 8 weeks of age. Animals were randomly assigned to treatment or control groups by cage. Additionally, randomization of the allocation of cages was performed according to an internal statistical software. Allocation of 12 animals per treatment group was defined according to a study by De Benedictis et al.17. The decision to allocate 6 (experiment 1) or 3 (experiment 2) animals to each of the RIG control groups were based on the findings of the preliminary experiment and corresponding ethical reasons. No blinding of investigator was implemented. No samples nor animals were excluded from the analyses.

Vaccines and rabies immunoglobulins. All vaccines used in this study were human inactivated whole virus vaccines from Sanofi (Lyon, France). HDCV is produced in human diploid cells (i.e., Medical Research Council cell strain 5 [MRC-5] cells), and PVRV is produced in Vero cells. The potency of all the vaccines used was of ≥ 2.5 IU/dose, determined by National Institute of Health (NIH) mouse potency tests. Each of the vaccines consisted of a freeze-dried formulation presented in a single-dose vial. The powder was reconstituted with 1 mL diluent for HDCV and 0.5 mL diluent for each of PVRV and PVRV-NG. To compare the 3 vaccines using the same vaccine dosage and considering that the largest volume possibly injectable by IM route in hamsters was of 100 µL, we choose to administer 1:10 human dose (HD) for all the vaccines. The hRIG and eRIG were...
from Sanofi (IMOGAM® Rabies-HT, Lyon, France) and The Thai Red Cross Society (TRCS ERIG®, Bangkok, Thailand), respectively.

**Experiments.** In a previous study, a hamster model was set up to compare monoclonal antibodies for rabies PEP with the conventional hRIG. We conducted a preliminary experiment to adapt this animal model for the evaluation of hRIG interference on the immunogenicity of PVRV-NG with a high dose of the vaccine (1:5 HD). The hamsters were randomized into 3 groups and administered with PVRV-NG, hRIG, or concomitant injections of PVRV-NG and hRIG (Fig. 1a). The animals were injected IM with a volume of 100 μL (1:5 HD) of PVRV-NG on Days 0, 3, 7, 14, and 28 (as the 5-dose Essen regimen) and/or a volume of 50 μL of hRIG (20 IU/kg) on Day 0.

Two successive experiments were then performed to compare the suppressive effect of RIG on the immunogenicity of PVRV-NG and the standard-of-care vaccines. In these experiments, vaccines were administered following the 4-dose Essen regimen omitting the fifth vaccine immunization usually performed on Day 28. The results from the preliminary experiment had shown evidence that this late immunization had no influence in the hamster model. In experiment 1, hamsters were randomized into 7 groups and administered with PVRV-NG, PVRV, HDCV, hRIG, or concomitant injections of any of the vaccines and hRIG (Fig. 1b). Animals were injected IM with a volume (1:10 HD) of 100 μL of HDCV, or 50 μL of PVRV or PVRV-NG on Days 0, 3, 7, and 14 (as the 4-dose Essen regimen) and/or a volume of 50 μL of hRIG (20 IU/kg) on Day 0. In experiment 2, hamsters were randomized to receive PVRV-NG (n = 12), PVRV (n = 12), HDCV (n = 12), hRIG (n = 6), or concomitant injections of any of the vaccines and hRIG (n = 12 in each group). Animals were injected IM with a volume (1:10 HD) of 50 μL of PVRV or PVRV-NG on Days 0, 3, 7, and 14 (as the 4-dose Essen regimen) and/or with a volume of 50 μL of hRIG (20 IU/kg) or eRIG (40 IU/kg) on Day 0.
Serological responses. Neutralizing antibody responses. The neutralizing antibodies in hamster serum samples were measured using the fluorescent antibody virus neutralization (FAVN) test, an adaptation of the rapid fluorescent focus inhibition test (RFFIT)\(^\text{18}\). Both tests are known to be equivalent when performed under good laboratory practices (GLP) and are recognized as the most accurate techniques to quantify RVNA. FAVN was performed according to the World Organization for Animal Health—Office International des Epizooties (OIE) and the Inovalys laboratory (Nancy, France) using threefold dilutions ranging from 1:6 to 1:354,294 of test sera or standard human rabies anti-immunoglobulin reference (RAI) serum (National Institute for Biological Standards and Control). Briefly, 50 µL of samples were mixed with 50 µL of challenge rabies virus (CVS-11) suspension containing 100 cell culture infectious dose 50% (CCID\(_{50}\)) of rabies virus in microtiter plates and incubated for 60 min in a humidified cell culture incubator. After incubation, Baby Hamster Kidney cells (BHK-21; American Type Culture Collection, Manassas, VA, USA; 50 µL, 4 × 10\(^6\) cells/mL) were added to the virus/serum mixture and incubated for 48 h at 37 °C. After incubation, cells were washed, fixed with 80% acetone for 30 min at room temperature (RT), and incubated with 50 µL of an appropriate dilution of fluorescein isothiocyanate (FITC)-conjugated anti-rabies antibody (Fujirebio Diagnostics, USA) for 30 min at RT. The content was discarded; the microplates were washed and air-dried at RT prior to incubating under a fluorescent microscope.

The titer was determined by comparing the results obtained for the hamster sera with those obtained for the anti-RIG standard and were defined as the serum dilution that reduced the number of fields containing infected cells by 50%, calculated using the CombiStats software (Council of Europe, Strasbourg, France). Titers were converted to IU/mL using the RAI as standard reference curve. The starting dilution was 1:6 so that the lower level of detection was 0.26 IU/mL. All samples with titers below the lower limit of detection (LOD) were assigned a titer of 0.13 IU/mL equal to half of the LOD.

The window of quantification at this 1:6 dilution was comprised between 0.26 and 3881 IU/mL.

Enzyme-linked immunosorbent assay (ELISA) response. The induction of rabies-specific immunoglobulin M (IgM) antibodies was assessed by an in-house ELISA using a commercially available anti-hamster µ-chain-specific conjugate (i.e. only detecting the IgM class-specific heavy chain portion in the Fc region) and PVRV-NG as the coating antigen\(^\text{19}\). No anti-hamster γ chain-specific conjugate (i.e. only detecting the IgG class-specific heavy chain portion in the Fc region) was commercially available. As an alternative, an anti-hamster total IgG (H + L) conjugate was used which detected both heavy (H) and light (L) chains of IgG antibodies with significant cross-reactivity with IgM antibodies. In summary, the ELISA of specific antibodies in the serum samples was performed with the following protocol. Greiner 96-well microplates were coated overnight at 4 °C with PVRV-NG vaccine in 0.05 M carbonate-bicarbonate buffer pH 9.6. Plates were then blocked for 1 h at 37 °C with 150 µL of phosphate buffered saline (PBS; pH 7.1)-0.05% Tween 20–1% (w/v) powdered skim milk (PBS-Tween–milk). All further incubations were carried out in a final volume of 100 µL, followed by 3 to 4 washings with PBS, pH 7.1–0.05% Tween. Serial two-fold dilutions of the serum samples performed in PBS-Tween-milk, starting from 1/100, were added to the wells and incubated for 90 min at 37 °C. After washings, an anti-hamster IgM µ chain-specific peroxidase conjugate (Jackson Laboratories, Baltimore, US) diluted in PBS Tween–1% milk at 1/5000 or 1/2000, respectively, was added and the plates were incubated for another 90 min at 37 °C. The plates were further washed and incubated in the dark for 30 min at RT with a ready-to-use 3,3′,5,5′-tetramethylbenzidine (TMB) substrate. The reactions were stopped with 100 µL of 1 N HCl. The optical density (OD) was measured at 450 to 650 nm with an automatic plate reader (Molecular Devices, San Jose, CA, USA). The blanks (mean value) were subtracted from the data. The antibody titers were calculated using the Excel or SoftMax Pro software and defined as the reciprocal dilution corresponding to an OD value of 1.0. All final titers were expressed in log scale. For each serum sample displaying an OD value below 1.0 at the first tested dilution of 1/100, the titer was defined as the OD value ×100.

Statistical analysis. Titers induced by vaccine immunization were statistically compared using a mixed model with product (PVRV-NG, PVRV, or HDCV alone or co-injected with hRIG or eRIG) and time as fixed factors and their interactions.

For group comparison (rabies vaccine + RIG versus rabies vaccine alone), a Tukey’s adjustment for multiple testing was performed. Only significant titer differences (i.e., titer decrease ≥ twofold) were considered biologically relevant considering the precision of the techniques.

A margin of error of 5% was used for effects of the main factors and of 10% for the interaction. The residuals of the model were studied to test the validity (normality, extreme individuals, etc.) of the model.

No replacement of missing or invalid values was made, and no imputation was performed for any of the analyses. A p-value < 0.05 was considered to indicate a statistically significant difference.
Results

Preliminary experiment to set up the interference hamster model with hRIG and PVRV-NG. The results from the preliminary experiment in hamsters showed a statistically significant interference of hRIG with the rabies seroneutralizing response induced by the PVRV-NG vaccine (1:5 HD). The mean FAVN titer measured at Day 7 post-PVRV-NG injections was 5.5-fold lower with concomitant injection of hRIG at Day 0 than without hRIG injection (p < 0.001). The effect of coadministration of hRIG on immunogenicity of PVRV-NG decreased with time and was not significant at later time-points (Fig. 2).

hRIG interference with PVRV-NG, PVRV, and HDCV vaccines in the hamster model. The results from experiment 1 showed that neutralizing antibodies achieved high levels as soon as Day 7 for the three vaccines administered alone (PVRV-NG, PVRV, and HDCV) with mean FAVN titers induced by PVRV-NG being significantly higher than that induced by HDCV (p < 0.001) and were not different from those elicited by PVRV (Fig. 3a).

At Day 7, the mean neutralizing titers measured for each of the vaccines with concomitant injection of hRIG were significantly lower than those measured with the corresponding vaccine alone (p = 0.01 for PVRV-NG and p < 0.001 for each of PVRV and HDCV, respectively) with 2.2-, 3.6-, and 10.5-fold-decrease for PVRV-NG,
PVRV, and HDCV, respectively, versus vaccine alone. At the following time-points, no more difference in the seroneutralizing titers was evidenced between vaccine groups with or without co-injection of hRIG (Fig. 3b). The group injected with hRIG alone did not show any detectable response at the tested time-points (D7, D14 and 28), as expected from the preliminary study.

The specific rabies ELISA IgM responses were in line with those measured by FAVN titration with mean responses following analogous kinetics as that of FAVN (Fig. 3c). At Day 7, the mean ELISA titers were significantly higher by twofold for PVRV-NG as compared with HDCV (p < 0.001) alone. The mean ELISA titers measured for the groups injected with vaccine and hRIG were significantly lower than those for the corresponding vaccine alone groups (p < 0.001), with 1.9- (below but very close to the twofold limit), 2.1-, and 3.9-fold decrease for PVRV-NG, PVRV, and HDCV vaccines, respectively (Fig. 3d).

**hRIG and eRIG interference with PVRV-NG and PVRV vaccines in the hamster model.** In experiment 2, a similar level of interference of hRIG and eRIG on the rabies neutralizing antibody response induced by the PVRV vaccine (4.0- and 4.4-fold decrease on the mean neutralizing titers in the presence of hRIG and eRIG, respectively, p < 0.001) was observed at an early time-point post vaccination (Day 7). As previously observed in experiment 1, such significant decreases were not observed at timepoints post Day 7. Conversely, only a slight decrease of 1.7-fold in the rabies seroneutralizing titer was observed when hRIG were co-injected with PVRV-NG versus PVRV-NG alone but was not deemed significant (i.e., below the twofold decrease limit). In the present experiment, no interference of RIG (either human or equine) on the immunogenicity of PVRV-NG was demonstrated (Fig. 4a,b). Additionally, at Day 7, the mean FAVN titer was significantly higher by three-fold for PVRV-NG as compared with PVRV (p < 0.001) in the presence of eRIG.

Estimation of the rabies-specific IgM antibody responses in the vaccinated animals showed a similar trend as that of FAVN, with titer decrease slightly less pronounced by ELISA than by seroneutralization. At Day 7, the geometric mean IgM titers measured for the groups injected with PVRV and hRIG/eRIG were significantly lower than those measured for the groups administered with vaccine alone (p < 0.001), with a titer decrease of 2.1- and 2.0-fold in the presence of hRIG and eRIG, respectively. At the following time-points, no more difference
was evidenced between the PVRV groups irrespective of the co-injection or not of hRIG or eRIG (Fig. 4c, d). No significant difference was evidenced between the PVRV-NG groups irrespective of the co-injection of hRIG or eRIG at any of the time points. The groups injected with hRIG or eRIG alone showed very low responses, slightly above the positive threshold.

**Discussion**

The delay in immune response development to rabies vaccine by RIG is a well-known phenomenon, which has been described in animal models as well as in humans. In clinical trials with various rabies vaccines and different PEP regimens, concomitant injection of RIG at Day 0 was described as inducing a transient interference on the seroneutralizing response measured in the treated subjects. The aim of this study was to compare the interference of RIG on the candidate vaccine versus commercially available rabies vaccines. The results demonstrated that RIG interference with PVRG-NG was similar or even less evident than that measured with our commercial rabies vaccines using a preclinical hamster model that has been described previously.

The aim of the preliminary experiment was to set-up the interference hamster model with a high dose of PVRV-NG (1:5 HD) and hRIG using a 5-dose Essen regimen, the regimen previously recommended by the WHO. A 5.5-fold decrease in the mean seroneutralizing titer in the group administered with both PVRV-NG and hRIG was observed as compared with PVRV-NG alone at Day 7. This clearly indicated the interference of hRIG on the immunogenicity of PVRV-NG. In experiments 1 and 2, we used the currently WHO’s 4-dose PEP Essen regimen and a vaccine dose of 1:10 HD, corresponding to the highest vaccine dose in relation to the maximum injectable volume in hamsters. Additionally, it was evident from the preliminary experiment with a 5-dose schedule that the fifth injection had no added value in the hamster model, as previously shown in humans.

![Figure 4](https://example.com/figure4.png)

**Figure 4.** Immunogenicity of PVRV-NG and standard-of-care vaccine in presence of human rabies immunoglobulin (hRIG) or equine rabies immunoglobulin (eRIG) administered by intramuscular (IM) injection according to post-exposure prophylaxis regimen. In experiment 2, adult female hamsters (n = 12 per group) were vaccinated on Days 0, 3, 7, and 14 by IM injection with 1:10 human dose of PVRV-NG or PVRV and co-injected or not on Day 0 with hRIG (20 IU/kg) or eRIG (40 IU/kg). (a) Serum rabies virus neutralizing antibody (RVNA) levels were measured by fluorescent antibody virus neutralization test (FAVN) on blood samples collected on Days -4 (4 days prior to Day 0; pre-bleed), 7, 14, and 28. The lower level of detection in FAVN was of 0.26 IU/mL as shown by the dotted line. The continuous black line indicating 0.5 IU/mL is the WHO specified standard serum RVNA titer considered as an adequate immune response to rabies vaccination in humans. Data are expressed as the mean ± SEM. (b) Serum RVNA titer measured 7 days after the first immunization. (c) Specific anti-rabies IgM titers were measured by ELISA on blood samples collected similarly as that of FAVN, D28 was not tested. (d) Individual ELISA titers measured 7 days after the first immunization. The mean value obtained with pre-test hamster sera is indicated with a specific continuous line.
To maximize the effect of RIG interference, we decided to inject hamsters with the same dosage of RIG as that used in humans, namely 20 IU/kg for hRIG and 40 IU/kg for eRIG.

The main goal of the study was to infer whether such interference was either lower or similar to that observed on commercial vaccines. The results from experiment 1 showed that PVRV-NG induced statistically significantly higher neutralizing antibodies than that induced by HDCV. Interestingly, the hRIG interference was statistically significant for PVRV-NG, PVRV, and HDCV in this model at Day 7, with 2.2-, 3.6-, and 10.5-fold decrease in mean FAVN titers versus each vaccine alone, respectively. Such an interference decreased with time and was not significant anymore at the later time-points. Whether the RIG was cleared after Day 7 is not known in this experiment. In humans, it has been shown that the peak of hRIG happens at around Day 7 and is gradually decreasing up to around 3 weeks, while the hRIG-induced interference on vaccines can still be seen on Day 14 and is undetectable by Day 42.

As the affordability and availability of the hRIG are key issues in endemic countries, eRIG has been used for the PEP regimens in some countries. Thus, experiment 2 was performed to assess the effect of eRIG on the rabies vaccines in the established hamster model using the Essen regimen. Of note, similar interferences were observed on PVRV-NG with eRIG or hRIG, although not statistically significant. However, we noted a statistically significant similar level of interference of hRIG and eRIG on the rabies neutralizing antibody response induced by PVRV with 4.0-fold and 4.4-fold decreases, respectively, in the mean neutralizing titers observed at an early time-point post vaccination (Day 7). Such a titer decrease was not statistically significant anymore at the following time-points. It is to be noted that, in both experiments, consistent levels of interference were highlighted when PVRV was co-injected with hRIG (3.6- and 4.0-fold decrease in experiment 1 and experiment 2, respectively) compared with the vaccine alone. It has previously been reported in a guinea-pig model that when rabies-specific antisera were concomitantly administered with rabies vaccine, the ability of animals to mount a protective immune response against the vaccine was lower for homologous antisera (i.e. raised in the same or in a different animal species, respectively)21. The stronger interference of passively transferred homologous antibodies on the vaccine response was associated with their longer persistence in the circulation than that of their heterologous counterparts. The high interference effect of homologous rabies-specific antibodies on rabies vaccine response was also observed with monoclonal antibodies in a mouse model22. Future studies will be needed to evaluate such interference on the vaccines used in this study. Noteworthy, both eRIG and hRIG, assessed herein, were heterologous immunoglobulins to the hamster model.

In the preliminary experiment, the seroneutralizing titer elicited at Day 7 by PVRV-NG in the presence of hRIG was 5.5-fold lower than that induced by the vaccine alone. In experiments 1 and 2, the interference of both hRIG and eRIG on PVRV-NG-induced seroneutralizing and ELISA titers was negligible. Indeed, titer fold decrease compared with vaccine alone was close to or below the 2.0-fold threshold that we considered as biologically relevant given the variability of biological responses associated with both techniques and animals. Although the clinical batch of PVRV-NG used in the preliminary experiment was different from that used in the experiments 1 and 2, both batches contained the same amount of G-protein. The 5.5-fold decrease in the mean FAVN titer in the preliminary experiment with 1:5 HD of PVRV-NG vaccine was replicated proportionally in experiment 1 with a 1:10 HD of the vaccine dose and respective 2.2-fold decrease. The decrease in the mean FAVN titer in experiment 2 with 1:10 HD of PVRV-NG vaccine was below but very close to the defined threshold. Above all, irrespective of vaccine interference introduced by concomitant RIG administration, all reported RVNA levels were still maintained well above 0.5 IU/mL at Day 7 onward, which was indicative of an adequate immune response to vaccination. With the data from all the experiments described herein, it can be inferred that hRIG or eRIG induced similar or even less interference on the PVRV-NG vaccine candidate as compared with that evidenced with commercial vaccines. The interference of RIG on PVRV-NG was similar to that on PVRV and tended to be lower than that on HDCV. The reasons of such results are still unknown and warrant further investigation.

The decrease in the antibody titer as measured by ELISA corroborated the findings from the FAVN, with the fold-decrease in titer slightly less pronounced by ELISA than by FAVN seroneutralization. The advantage of the ELISA test is its convenience and rapidity to generate data. Although the seroneutralization test is more laborious and time consuming, it remains the gold standard to measure immunogenicity induced by rabies vaccines.

The induction of rabies-specific IgM antibodies was assessed by an in-house ELISA using a commercially available anti-hamster μ chain-specific conjugate and PVRV-NG as the coating antigen. As no anti-hamster γ chain-specific conjugate was commercially available, anti-rabies IgG antibodies could not be strictly titrated. Alternatively, we used an anti-hamster total IgG (H + L) conjugate capable of detecting IgG and significantly cross-reacting with IgM antibodies. With this conjugate, similar results to those measured with the IgM conjugate were found, indicating that the IgM response was preponderant (data not shown). IgM is indeed the first class of immunoglobulin appearing during onset of an immune response, and such antibodies were of interest gate were found, indicating that the IgM response was preponderant (data not shown). IgM is indeed the first class of immunoglobulin appearing during onset of an immune response, and such antibodies were of interest.
cells. It was postulated that the immunocomplexes could exert a negative signaling on immature IgM receptor-bearing primary B cells, preventing them from differentiation into antibody-secreting plasma cells. Whether this mechanism transiently occurred in our present studies is not known.

The results of the present study showed that the potential interference of RIG on PVRV-NG in a hamster model was similar or even less pronounced by our PVRV-NG as compared with our commercial vaccines. In future investigations, the extrapolation of these results needs to be confirmed in human clinical trials to verify the predictivity of the hamster model. The clinical development plan of the vaccine candidate includes a phase III-simulated Essen PEP regimen study in healthy adults that aims: (i) to demonstrate the non-inferiority of PVRV-NG versus PVRV and HDCV vaccines when co-administered with hRIG and (ii) to describe the hRIG interference in an arm of PVRV-NG administered as standalone (NCT03965962). This study will help in further elucidating the extent and nature of RIG interference on the new candidate vaccine especially when the full quantity of hRIG is administered by IM route as the most stringent evaluation in healthy participants. On the contrary, the clinical practice has changed after the WHO 2018 recommendations, in which the RIG is infiltrated into and around the wound and the remaining RIG is no longer administered intramuscularly at a distant site.

Conclusion

In this study, we confirmed the transient interference of human and equine RIG on the rabies neutralizing antibody responses induced by the PVRV and HDCV commercial vaccines in a hamster model and demonstrated that such interference was similar or even less pronounced for the PVRV-NG vaccine candidate.

Data availability

The datasets generated during the current study are available from the corresponding author on reasonable request.

Received: 3 November 2021; Accepted: 30 March 2022
Published online: 21 April 2022

References

1. Rabies Factsheet. https://www.who.int/news-room/fact-sheets/detail/rabies (2021).
2. World Health, O. Rabies vaccines: WHO position paper, April 2018—recommendations. Vaccine 36, 5500–5503. https://doi.org/10.1016/j.vaccine.2018.06.061 (2018).
3. Hampson, K. et al. Estimating the global burden of endemic canine rabies. PLoS Negl. Trop. Dis. 9, e0003709. https://doi.org/10.1371/journal.pntd.0003709 (2015).
4. Pichon, S. et al. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: Results from a randomized controlled phase-II trial. Vaccine 31, 2295–2301. https://doi.org/10.1016/j.vaccine.2013.02.058 (2013).
5. Li, R. et al. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab(R) when administered according to a post-exposure regimen in healthy children and adults in China. Vaccine 31, 5940–5947. https://doi.org/10.1016/j.vaccine.2013.10.043 (2013).
6. The immunological basis for immunization series: module 17: rabies vaccines. http://www.who.int/immunization/documents/policies/WHO_IVB_ISBN9789241513371/en/(World Health Organization, 2017).
7. WHO. Rabies Working Group Report, SAGE meeting October 2017, http://www.who.int/immunization/sage/meetings/2017/october/1_Background_paper_WG_RABIES_final.pdf?ua=1 (2017).
8. Gogtay, N. J. et al. Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: A phase 2/3, randomized, single-blind, non-inferiority, controlled study. Clin. Infect. Dis. 66, 387–395. https://doi.org/10.1093/cid/ciz791 (2018).
9. Lang, J., Simanjuntak, G. H., Soerjosembo, S. & Koesharyono, C. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: A field trial in Indonesia. MA505 Clinical Investigator Group. Bull. World Health Organ. 76, 491–495 (1998).
10. Salva, E. P., Dimanno, E. M., Villarana, J. R. R. & Suquila, J. T. An evaluation of the safety and potency of equine rabies immunoglobulin through measurement of suppression on vaccine-induced antibody production among healthy volunteers. Philippine J. Intern. Med. 52, 7 (2014).
11. Preiss, S. et al. Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: A systematic literature review and meta-analysis. Expert Rev. Vaccines 17, 525–545. https://doi.org/10.1080/14760584.2018.1473765 (2018).
12. Audran, R. et al. Poor immune response to rabies post-exposure prophylaxis: An attempt to understand the underlying mechanisms. ISM Trop. Med. Res. 1(2), 1009 (2016).
13. Tulek, N., Senocak, H., Yetkin, A., Un, H. & Aylan, O. Antibody response achieved by different rabies prophylaxis methods. Int. J. Infect. Dis. 10, 87–88. https://doi.org/10.1016/j.ijid.2005.02.007 (2006).
14. Matson, M. A. et al. Safety and efficacy results of simulated post-exposure prophylaxis with human immune globulin (HRIG; KEDRAB) co-administered with active vaccine in healthy subjects: A comparative phase 2/3 trial. Hum. Vaccin. Immunother. 16, 452–459. https://doi.org/10.1080/21645515.2019.1656967 (2020).
15. Hobot-Porter, N. et al. Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure. Hum. Vaccin. Immunother. 17, 2090–2096. https://doi.org/10.1080/21645515.2020.1854000 (2021).
16. Sampath, G. et al. Comparison of the immunogenicity and safety of the purified chick embryo cell rabies vaccine manufactured in India and Germany: A randomized, single blind, multicentre, phase IV clinical study. Hum. Vaccin. Immunother. 13, 1531–1538. https://doi.org/10.1080/21645515.2017.1307483 (2017).
17. De Benedictis, P. et al. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Mol. Med. 8, 407–421. https://doi.org/10.15252/emmm.201505986 (2016).
18. Cluet, F., Aubert, M. & Sagne, L. Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J. Immunol. Methods 212, 79–87 (1998).
19. Wansnieuw, M. et al. Evaluation of a rabies ELISA as an alternative method to seroneutralisation tests in the context of international trade of domestic carnivores. J. Virol. Methods 195, 211–220. https://doi.org/10.1016/j.jviromet.2013.10.021 (2014).
20. Vodopija, I. et al. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 6, 283–286. https://doi.org/10.1016/0264-410x(88)90225-3 (1988).
21. Archer, B. G. & Dierks, R. E. Effects of homologous or heterologous antiserum on neutralizing antibody response to rabies vaccine. *Bull World Health Organ.* 39, 407–417 (1966).

22. Rupprecht, C. E. et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. *Vaccine* 27, 7141–7148. https://doi.org/10.1016/j.vaccine.2009.09.029 (2009).

23. Lang, J. et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. *Biologicals* 26, 7–15. https://doi.org/10.1016/j.biologicals.2017.01.017 (1998).

24. Helmick, C. G., Johnstone, C., Sumner, J., Winkler, W. G. & Fager, S. A clinical study of Merieux human rabies immune globulin. *I. Biol. Stand.* 10, 357–367. https://doi.org/10.1016/s0092-1157(82)80013-9 (1982).

25. Schumacher, C. L., Erdl, H. C., Koprowski, H. & Dietzschold, B. Inhibition of immune responses against rabies virus by monoclonal antibodies directed against rabies virus antigens. *Vaccine* 10, 754–760. https://doi.org/10.1016/0264-410x(92)90510-q (1992).

**Acknowledgements**

The authors thank Sylvie Commandeur and Nadine Petiot for their remarkable technical assistance, Julie Piolat for statistical analysis, Denitsa Petkova and her team at Voxcan for animal handling, and Sylvie Poliak and her team at Inovalys Nancy France for seroneutralizing antibody measurement. Scientific writing support was provided by Surela Banerjee, PhD (Sanofi). Editorial assistance and manuscript coordination support were provided by Roopsha Brahma, PhD (Sanofi). The study was funded by Sanofi.

**Author contributions**

M.C.B. and F.G.M. conceived the study. M.C.B., F.B., and F.G.M. designed the experiments. M.C.B., F.B., and A.C.P.P. were involved with data analysis and interpretation. All authors were involved in the drafting of the manuscript or revising it critically for important intellectual content. In addition, all authors provided final approval of the manuscript.

**Funding**

This study was funded by Sanofi. Sanofi was involved in data acquisition and analysis, and review and approval of the final report for publication.

**Competing interests**

MCB was an employee of Sanofi at the time of submission of the manuscript. FB, ACP, and FGM are currently employees of Sanofi. ACP, MCB, and FB may hold shares in the company.

**Additional information**

Correspondence and requests for materials should be addressed to M.-C.B.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022